Unitaid’s Vector Control Portfolio

RBM Vector Control Working Group Meeting

Matthew Black & Kelsey Barrett
February 2023
Unitaid: A global development agency

**VISION**

Equitable access to health innovations to ensure healthy lives and promote well-being for all

**MISSION**

We expand the reach of the best health products for those who need them most

Number of Unitaid projects in countries, 2020

- More than 10 projects
- 8-9 projects
- 6-7 projects
- 4-5 projects
- 2-3 projects
- 1 project
Unitaid Brings Lifesaving Tools to People in LMICs

Without Unitaid vital health tools would not exist today

- All HIV medicines in low- and middle-income countries (LMICs)
- All tests to detect TB bacterial load and all medicines to treat drug-resistant TB
- All tools to prevent malaria
- All paediatric formulations for HIV, TB, malaria
  Groundwork for national cervical cancer elimination
Unitaid accelerates equitable access to innovative health products

<table>
<thead>
<tr>
<th>Access areas</th>
<th>Innovation &amp; Availability</th>
<th>Quality</th>
<th>Affordability</th>
<th>Supply &amp; Delivery</th>
<th>Demand &amp; Adoption</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examples of Unitaid interventions</td>
<td>Late stage product development/reformulations</td>
<td>Prequalification</td>
<td>Price negotiations</td>
<td>Distribution optimization</td>
<td>Global Policy &amp; Guidelines</td>
</tr>
<tr>
<td></td>
<td>Post registration clinical trials</td>
<td>In-country registration</td>
<td>Pooled procurement</td>
<td>Technical Assistance/Incentives to manufacturers</td>
<td>Country Policy and Guidelines</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Local manufacturing</td>
<td>Volume guarantee</td>
<td>Capacity building</td>
<td>Large-scale pilots</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Forecasting</td>
<td>Evidence generation: feasibility, cost-effectiveness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Behavior change</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Co-pay</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Intellectual Property</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2023-2027 Strategic Objectives and Programmatic Priorities

**Strategic Objectives**

1. **Accelerate the introduction and adoption of key health products**
   - Boost the development of fit-for-purpose health products
   - Use market shaping approaches to enable suitable, affordable, quality supply
   - Support product adoption and scale up in countries as part of simple, effective and evidence-based models of care

2. **Create systemic conditions for sustainable, equitable access**
   - Establish an enabling environment for access, including IP and regulation
   - Support innovative supply models & approaches, including local manufacturing and technology transfer
   - Disseminate knowledge and evidence on access

3. **Foster inclusive and demand-driven partnerships for innovation**
   - Maximise the engagement of affected communities and responsiveness to their needs
   - Maximise alignment and synergies with governments, in-country stakeholders, affected communities and civil society organisations
   - Further develop global alliances for product scale up

**Programmatic Priorities**

- **Reinforces** our traditional core area of work: e.g., grant making, especially for HIV, TB, malaria; scale-up
- **Formalizes** work in areas we introduced and demonstrated, e.g., local manufacturing; engagement with affected communities
- **Expands** our mandate to new areas, e.g., making healthcare greener; responding to global health emergencies; disseminating knowledge and evidence on access
Programmatic priorities

- HIV & co-infections
  - Sustain effectiveness of prevention & treatment
- TB
  - Enable TB prevention tools for high-risk groups
- Malaria
  - Introduce and optimize prevention tools
    - Improve access to quality case management
- Women & children’s health
  - Improve access to better tools for safe pregnancy and birth for women and newborns
- Women & children’s health
  - Respond to global health emergencies
- Improve quality of clinical care packages for COVID-19

- Drive HCV elimination through testing and prevention
  - Accelerate adoption of new drugs and regimens
- Increase access to screen & treat for cervical cancer and STIs
  - Improve child survival with triage and treatment tools

- Accelerate access to self-testing & integrated diagnostics
- Long acting & new technologies
- Intellectual Property, regulatory and innovative supply models

Decentralize testing and treatment for COVID-19

Cross-linkages with improving health outcomes for women and children
Malaria priority 1: Introduce and optimize prevention tools (vector control, chemoprevention, vaccines)

Adoption of new tools and approaches, in the most impactful combinations

Illustrative portfolio of topics & interventions

- **Short-term (current):** optimize delivery of malaria chemoprevention (IPTi) and ensure access to quality-assured drugs; evaluate new vector control tools (spatial repellents and ivermectin)

- **Mid-term (2-3 years):** optimize deployment of prevention tools e.g. through at-scale pilots, innovative delivery approaches, and generating evidence to guide policy and prioritization.

- **Long-term (4-5 years):** lay the groundwork for transformational new prevention tools (e.g. genetically modified mosquitos, long-acting technologies and vaccines)
Unitaid’s current malaria portfolio (US$ 327 million)

Prevent

- Chemotherapy – pregnant women*
- Chemotherapy – infants
- Vaccine
- New ITNs
- New VC tools
- Long-acting tech

Test

- Refer severe
- Treat

Case management

Severe Malaria *

Integrated fever management

Diagnosis and treatment of P. vivax

Treat

*Recently closed
New Nets Project

*Introduce new long-lasting insecticide-treated nets (LLINs) in areas of insecticide resistance*

**Lead Grantee**
Innovative Vector Control Consortium (IVCC)

**Grant Period**
2018-2022

**Grant Value**
US$66M

**Project countries**
Benin, Burkina Faso, Rwanda, Mali, Mozambique, Nigeria, Cote d’Ivoire, Liberia, Ghana, DRC, Malawi, Niger, Cameroon, and Burundi

*Grant Impact*
"Introduce new long-lasting insecticide-treated nets (LLINs) in areas of insecticide resistance*
Advancing Spatial Repellents for Vector-borne Disease Control

Evaluate slow-release repellents that drive mosquitoes from inhabited areas

Lead Grantee: University of Notre Dame
Grant Period: 2019 - 2024
Grant Value: US$ 33.7M
Project Countries: Kenya, Mali, Sri Lanka, Uganda
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)

- **Lead Grantee**: ISGlobal
- **Grant Period**: 2019 - 2024
- **Grant Value**: US$ 25M
- **Project Countries**: Mozambique, Kenya

**Grant Impact**: Develop a new complementary new-class vector control tool, ivermectin (endectocides)
IMPACT: Long-acting injectable formulation of ivermectin as a new vector control tool to reduce malaria transmission

<table>
<thead>
<tr>
<th>Technology</th>
<th>Target Indications</th>
</tr>
</thead>
</table>
| **BEPO® advanced injectable in-situ forming depot**  
  • uses a combo 2 biodegradable copolymers + solvent as excipients.  
  • Drug release from days to months.  
  • Simple manufacturing process  
  • Contraception + HIV PreP funded by BMGF | **BEPO®- IVM:**  
  Injectable subcutaneous 3-month long-acting formulation of ivermectin |

<table>
<thead>
<tr>
<th>Target Indications</th>
<th>Technology</th>
</tr>
</thead>
</table>
| **Malaria vector control** | **BEPO® advanced injectable in-situ forming depot**  
  • uses a combo 2 biodegradable copolymers + solvent as excipients.  
  • Drug release from days to months.  
  • Simple manufacturing process  
  • Contraception + HIV PreP funded by BMGF |

<table>
<thead>
<tr>
<th>Timeline*</th>
<th>Preclinical Development</th>
<th>Clinical Development</th>
<th>Regulatory &amp; Commercialization</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020 – 2023</td>
<td>2023 – 2025</td>
<td>2026</td>
<td></td>
</tr>
</tbody>
</table>

*Unitaid funded IMPACT project – 2020 – 2023 up to initiation of clinical development.
Key malaria prevention tools:

- Next-generation LLINs
- Malaria vaccines
- Chemoprevention tools and approaches
- Spatial repellents
- Ivermectin MDA